» Articles » PMID: 20558556

The Changing Picture of Patients with Pulmonary Arterial Hypertension in the United States: How REVEAL Differs from Historic and Non-US Contemporary Registries

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2010 Jun 19
PMID 20558556
Citations 154
Authors
Affiliations
Soon will be listed here.
Abstract

Background: REVEAL (The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) provides current demographics of patients with group 1 pulmonary arterial hypertension (PAH) in the United States.

Methods: A total of 2,967 patients with PAH diagnosed based on right-sided heart catheterization were enrolled in REVEAL between March 2006 and September 2007. Demographics from the REVEAL patient cohort and REVEAL subpopulations (matched by inclusion criteria to other registries) were compared with historic US registry data and other contemporary US and non-US national PAH registries by inclusion criteria, including the National Institutes of Health (NIH) PAH registry and the French PAH registry.

Results: REVEAL patients matched to NIH registry patients were older at diagnosis (mean ± SE, 44.9 ± 0.6 years vs 36.4 ± 1.1 years; difference, 8.5 ± 1.4; P < .001) and more likely to be women (78.7 ± 1.2% vs 63.1 ± 3.5%; P < .001). REVEAL patients matched to French registry patients had similar age and severity at diagnosis, but REVEAL patients were more likely to be women (79.8 ± 0.8% vs 65.3 ± 1.8%; P < .001) and obese (BMI, ≥ 30 kg/m(2), 32.5 ± 1.0% vs 14.8 ± 1.4%; P < .001), whereas French patients were more likely to have HIV-associated PAH (6.2% vs 2.3%). The female preponderance is similar to that in other US-based contemporary registries.

Conclusions: At diagnosis, REVEAL patients were older than NIH registry patients and similar in age to patients enrolled in contemporary registries. Compared with NIH and contemporary European and UK registries, there was a striking preponderance of women, and REVEAL patients were more likely to be obese. These observations and the difference in HIV-associated PAH between REVEAL and other non-US contemporary registries warrant further investigation.

Trial Registry: ClinicalTrials.gov; No.: NCT00370214; URL: clinicaltrials.gov.

Citing Articles

Long-term trends in the burden of pulmonary arterial hypertension in China and worldwide: new insights based on GBD 2021.

Xu Z, Ding J, Liang R, Xie S Front Med (Lausanne). 2025; 11():1502916.

PMID: 39839629 PMC: 11748298. DOI: 10.3389/fmed.2024.1502916.


Reassessing Pulmonary Hypertension Classification: Utilizing Criteria for Heart Failure with Preserved Ejection Fraction Instead of Pulmonary Arterial Wedge Pressure.

Park D, Fuge J, Kamp J, Harrigfeld B, Berliner D, Hoeper M J Clin Med. 2025; 13(24.

PMID: 39768504 PMC: 11728240. DOI: 10.3390/jcm13247582.


Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension.

Reddy Y, Frantz R, Hassoun P, Hemnes A, Horn E, Leopold J J Am Coll Cardiol. 2024; 84(22):2196-2210.

PMID: 39453363 PMC: 11760158. DOI: 10.1016/j.jacc.2024.08.061.


Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

Lancet Respir Med. 2024; 13(1):69-79.

PMID: 39433052 PMC: 11698691. DOI: 10.1016/S2213-2600(24)00295-9.


Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.

McLaughlin V, Sitbon O, Chin K, Galie N, Hoeper M, Kiely D Eur J Heart Fail. 2024; 26(11):2379-2391.

PMID: 38966990 PMC: 11659495. DOI: 10.1002/ejhf.3319.